U.S. Guillain-Barré Syndrome Market Size, Share & Forecast 2026–2032

ID: MR-11582 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Guillain-Barré Syndrome Treatment Market
  • ✓Market Size 2024: USD 1.12 billion
  • ✓Market Size 2032: USD 1.58 billion
  • ✓CAGR: 4.4%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Plasma Supply Concentrates Power: Competitive advantage in U.S. GBS care rests on plasma collection, not drug discovery. CSL Behring, Takeda, Grifols and Octapharma control most donor center networks, so immunoglobulin supply tightness allocates share at the hospital pharmacy level.
FINDING 02
Standard Therapy Will Persist: Complement inhibitors will not displace immunoglobulin as first-line therapy. Alexion's eculizumab failed its pivotal GBS trial, and no successor has reported pivotal GBS results, so plasma-derived IVIG remains the reimbursed default through 2032.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Formulary Positions Early: Plasma-derived product suppliers and specialty distributors should secure formulary contracts with Vizient and Premier before the 2027 renewal cycle, prioritizing neurology centers in the South and Midwest. Locking volume before IRA-driven price pressure reshapes tenders protects margin against commoditization.

Guillain-Barré Syndrome Competitive Overview in the U.S.

The U.S. Guillain-Barré syndrome (GBS) treatment market is moderately concentrated. Four plasma-derived immunoglobulin manufacturers, CSL Behring, Takeda, Grifols and Octapharma, supply most intravenous immunoglobulin (IVIG) volume used for GBS, while plasma exchange equipment is dominated by Terumo BCT and Haemonetics. Because no therapy carries a GBS-specific FDA label, these suppliers compete for hospital protocol inclusion rather than indicated prescriptions, so procurement is driven by formulary committees instead of physician brand loyalty.

Domestic players are fewer and smaller than multinationals. ADMA Biologics is the leading U.S.-headquartered firm with an integrated plasma collection network, giving it sourcing control that foreign competitors often secure through contract collection. In this country, competitive advantage depends on plasma sourcing depth, CBER biologics licensure and inclusion in group purchasing agreements with Vizient and Premier, far more than on proprietary molecules.

Demand Drivers Shaping Guillain-Barré Syndrome Care in the U.S.

Rising diagnosis among older adults is the first driver. Roughly 3,000 to 6,000 Americans develop GBS annually, and incidence climbs with age, pushing neurology referrals into hospital intensive care units. Immunoglobulin demand also benefits from shared supply lines with chronic inflammatory demyelinating polyneuropathy (CIDP). Takeda's Gammagard Liquid and CSL Behring's Privigen carry CIDP labels, so suppliers with the broadest multi-indication immunoglobulin portfolios capture volume that GBS prescribing alone could not sustain.

The second driver is heightened vaccine-safety surveillance. Post-licensure reports tied to the Janssen COVID-19 vaccine and to seasonal and zoster vaccines have kept FDA and CDC monitoring active through VAERS and the Vaccine Safety Datalink, raising clinician awareness of GBS. The third driver is the expansion of plasma exchange capacity at community hospitals, which favors apheresis suppliers such as Terumo BCT and Haemonetics that bundle disposable kits with long-term service agreements.

Competitive Restraints and Market Challenges

Price competition is the sharpest constraint. IVIG products are therapeutically interchangeable within GBS protocols, so group purchasing tenders compress unit prices and push suppliers to compete on contract terms, rebates and supply reliability. Smaller producers without fractionation scale face margin erosion as plasma input costs rise, while larger players offset pressure through breadth across primary immunodeficiency and CIDP indications.

Talent and infrastructure gaps limit competitive reach. U.S. hospitals face shortages of neurointensivists and trained apheresis nurses, restricting plasma exchange largely to academic medical centers in metropolitan markets. Compliance with current good manufacturing practice and FDA plasma establishment inspections adds fixed costs that favor incumbents, while rural hospitals in the Mountain West and Deep South remain underserved, leaving distribution gaps for regional specialty distributors.

Growth Opportunities for Market Players

The largest opportunity is a GBS-specific label. Alexion's eculizumab trial in GBS did not meet its primary endpoint, creating a window for next-generation complement inhibitors or neonatal Fc receptor blockers. argenx's efgartigimod, approved for CIDP in 2024, is a logical candidate for GBS trial design, and the first firm to secure a GBS indication would reset hospital protocols and command premium pricing.

Home-based maintenance represents a second opening. Subcutaneous immunoglobulin products such as CSL Behring's Hizentra, approved for immunodeficiency and CIDP maintenance, allow patients to continue therapy outside hospitals. This creates recurring volume for home infusion operators and specialty pharmacies that secure Medicare Part B home coverage arrangements across the multi-month recovery window.

Regulatory and Policy Environment

The FDA's Center for Biologics Evaluation and Research regulates plasma-derived immunoglobulins under the Public Health Service Act and 21 CFR Parts 600 through 640, setting licensure, donor screening and manufacturing standards that determine which firms can compete. The Orphan Drug Act grants seven years of market exclusivity to any future GBS-labeled biologic, a direct incentive for new entrants. Vaccine safety monitoring runs through VAERS and the CDC Vaccine Safety Datalink, with ACIP shaping national vaccine recommendations.

The Centers for Medicare and Medicaid Services shape pricing through Medicare Part B reimbursement, which pays immunoglobulin at average sales price plus a statutory add-on, and through Part B home IVIG coverage under durable medical equipment rules. The Inflation Reduction Act's drug price negotiation framework, phasing in for Part B drugs from 2028, and the 340B Drug Pricing Program both alter hospital purchasing economics, reshaping which suppliers win contracts.

Competitive Outlook for Guillain-Barré Syndrome in the U.S.

By 2032, competition will remain anchored by plasma-derived IVIG, with CSL Behring, Takeda, Grifols and Octapharma holding leadership through fractionation scale and CIDP label breadth. Share will shift toward suppliers with vertically integrated U.S. plasma collection, and domestic capacity will become a procurement differentiator as hospital systems prioritize supply security over marginal price advantages.

Competitive change will come from label expansion and apheresis equipment standardization rather than from new molecules alone. Any firm that secures a GBS indication in the early 2030s will reset formulary positions, while Terumo BCT and Haemonetics benefit from ICU plasma exchange protocols. Price erosion from IRA negotiation will push smaller immunoglobulin producers toward consolidation or licensing partnerships.

Market at a Glance

MetricValue
Market Size 2024USD 1.12 billion
Market Size 2032USD 1.58 billion
Growth Rate (CAGR)4.4%
Most Critical Decision FactorSecured plasma supply and hospital formulary contract access
Largest RegionSouthern United States
Competitive StructureModerately concentrated oligopoly

Leading Market Participants

  • CSL Behring
  • Takeda Pharmaceuticals
  • Grifols
  • Octapharma
  • Kedrion Biopharma
  • GC Biopharma
  • ADMA Biologics
  • Alexion Pharmaceuticals
  • Haemonetics
  • Terumo BCT

Regulatory and Policy Environment

The FDA's Center for Biologics Evaluation and Research regulates plasma-derived immunoglobulins under the Public Health Service Act and 21 CFR Parts 600 through 640, setting licensure, donor screening and manufacturing standards that determine which firms can compete.

Market Segmentation

Frequently Asked Questions

CSL Behring, Takeda, Grifols and Octapharma supply most intravenous immunoglobulin used in U.S. GBS care. Their share rests on plasma fractionation scale and broad immunoglobulin portfolios.
IVIG products are largely interchangeable within GBS protocols, so buyers select suppliers through group purchasing tenders. Suppliers then compete on rebates, contract terms and supply reliability.
No GBS-specific biologic is currently approved in the United States, and clinicians use IVIG and plasma exchange off-label for GBS. This gap creates a label expansion opportunity for future entrants.
Firms with integrated plasma collection networks control input costs and supply continuity, which hospital systems increasingly prioritize. Suppliers dependent on contract collection face higher margin pressure.
Home infusion and specialty pharmacy channels offer lower entry barriers than hospital tenders. Players that secure Medicare Part B home coverage arrangements can build recurring volume.

Market Segmentation

By Treatment Modality
  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Complement Inhibitors
  • Subcutaneous Immunoglobulin
  • Supportive Care
By End User
  • Hospitals
  • Specialty Neurology Clinics
  • Ambulatory Infusion Centers
  • Home Care Settings
By Distribution Channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Group Purchasing Organizations
  • Direct Tender Contracts

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 Guillain-Barré Syndrome in the U.S. - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Treatment Modality Insights
4.1 Intravenous Immunoglobulin
4.2 Plasma Exchange
4.3 Complement Inhibitors
4.4 Subcutaneous Immunoglobulin
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Specialty Neurology Clinics
5.3 Ambulatory Infusion Centers
5.4 Home Care Settings
5.5 Others
Chapter 06 Competitive Landscape
6.1 Market Players
6.2 Leading Market Participants
6.2.1 CSL Behring
6.2.2 Takeda Pharmaceuticals
6.2.3 Grifols
6.2.4 Octapharma
6.2.5 Kedrion Biopharma
6.2.6 GC Biopharma
6.2.7 ADMA Biologics
6.2.8 Alexion Pharmaceuticals
6.2.9 Haemonetics
6.2.10 Terumo BCT
6.3 Regulatory Environment
6.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.